Phaseline

Targets › HA

HA: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Infectious disease, Vaccines; next expected readout Dec 2026.

Open in Phaseline: the race on HA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SanofiPandemic flu H5 HA mRNA SD2 vaccine
mRNA vaccine encoding H5 hemagglutinin
HAPhase 1Pandemic Influenza ImmunizationDec 2026
National Institute of Allergy and Infectious Diseases (NIAID)VRC-FLUMOS0122-00-VP (SteMos1)
Quadrivalent influenza HA stem vaccine composed of pentameric scaffold with trimeric HA st
HAPhase 1Influenza PreventionAug 2027

Conditions

Influenza Prevention (1) Pandemic Influenza Immunization (1)

Modalities

protein or peptide (1), other (1)

Companies

National Institute of Allergy and Infectious Diseases (NIAID) (1) Sanofi (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.